Dystrogen Therapeutics has developed new multi-chimeric cells for treating patients with Sickle Cell Diseases. Our multi chimeric cells are created via cell fusion of 3 or more cells of hematopoietic origin from three different donors. The cells of hematopoietic origin are isolated from bone marrow, umbilical cord blood, or peripheral blood.
Multi chimeric cells express surface antigens specific for the respective multiple cell donors. Our therapy mitigates the side effects of immunosuppression and conditioning regimens as well as enhances hematopoietic stem cell engraftment without development of graft-versus-host-disease (GvHD) and responds to the issue of limited availability of the matched donors by offering multi-chimeric cells as an alternative therapeutic option for patients requiring stem cell or bone marrow transplant.